AN2 Therapeutics, Inc., (ANTX) News

AN2 Therapeutics, Inc., (ANTX): $2.47

0.09 (+3.78%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

Add ANTX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#289 of 362

in industry

Filter ANTX News Items

ANTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ANTX News From Around the Web

Below are the latest news stories about AN2 THERAPEUTICS INC that investors may wish to consider to help them evaluate ANTX as an investment opportunity.

One AN2 Therapeutics Insider Raised Their Stake In The Previous Year

Looking at AN2 Therapeutics, Inc.'s ( NASDAQ:ANTX ) insider transactions over the last year, we can see that insiders...

Yahoo | November 12, 2023

AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights

MENLO PARK, Calif., November 09, 2023--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended September 30, 2023.

Yahoo | November 9, 2023

AN2 Therapeutics, Inc. (ANTX) Is a Great Choice for 'Trend' Investors, Here's Why

AN2 Therapeutics, Inc. (ANTX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Yahoo | November 6, 2023

AN2 Therapeutics to Present at Upcoming Investor Conferences

MENLO PARK, Calif., November 06, 2023--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that company management will participate in two upcoming investor conferences in November.

Yahoo | November 6, 2023

AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease

MENLO PARK, Calif., October 18, 2023--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that it has received an exclusive license from the University of Georgia Research Foundation to advance the development of a boron-containing small molecule for Chagas disease. These boron-based molecules were originally discovered by researchers at Anacor

Yahoo | October 18, 2023

AN2 Therapeutics, Inc. (NASDAQ:ANTX) stock most popular amongst individual investors who own 29%, while private equity firms hold 27%

Key Insights The considerable ownership by individual investors in AN2 Therapeutics indicates that they collectively...

Yahoo | October 16, 2023

AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023

MENLO PARK, Calif., October 11, 2023--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced two oral presentations and three poster presentations at the Infectious Disease Society of America (IDSA) IDWeek 2023 Conference from October 11-15, 2023 in Boston, Massachusetts. AN2 Therapeutics is currently enrolling patients in the Phase 3 part of its p

Yahoo | October 11, 2023

Is Adagene (ADAG) Outperforming Other Medical Stocks This Year?

Here is how Adagene Inc. Sponsored ADR (ADAG) and AN2 Therapeutics, Inc. (ANTX) have performed compared to their sector so far this year.

Yahoo | September 27, 2023

AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria

MENLO PARK, Calif., September 26, 2023--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that it has received a research grant from the Bill & Melinda Gates Foundation to discover novel, boron containing small molecules for the treatment of tuberculosis and malaria. Funding from the Gates Foundation will support the discovery of novel inhibit

Yahoo | September 26, 2023

AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease

MENLO PARK, Calif., September 13, 2023--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that it has commenced the Phase 3 part of its Phase 2/3 clinical trial evaluating once-daily, oral epetraborole for treatment-refractory MAC lung disease after completing Phase 2 enrollment. The Phase 2/3 clinical trial is expected to support regulatory f

Yahoo | September 13, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!